13 completed, 4 unknown, 3 withdrawn, 2 terminated. 24 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 13, Unknown 4, Withdrawn 3, Terminated 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Unknown 3 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow Uremia: new trials by email Literature Review of Uremia trials Research Report on Uremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-11-01 | 2026-04-13 |
| A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole Dipyridamole 50mg tid - Restless Leg Syndrome Due to Uraemia | Phase 2 / Phase 3 | Recruiting | Yunfeng Xia | 80 | 2025-09-20 | 2026-04-22 |
| A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS INM004, SoC - Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease | Phase 2 | Completed | Inmunova S.A. | 57 | 2022-10-06 | 2023-08-21 |
| Eculizumab to Cemdisiran Switch in aHUS cemdisiran, Placebos - Atypical Hemolytic Uremic Syndrome | Phase 2 | Withdrawn | Mario Negri Institute for Pharmacological Research | 2021-01-01 | 2021-03-10 | |
| Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS INM004, Placebo - Bloody Diarrhea, STEC, Unspecified | Phase 2 / Phase 3 | Terminated | Inmunova S.A. | 11 | 2019-07-17 | 2023-07-19 |
| Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Eculizumab - Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 23 | 2018-08-03 | 2023-09-21 |
| A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome Cemdisiran - Atypical Hemolytic Uremic Syndrome | Phase 2 | Withdrawn | Alnylam Pharmaceuticals | 2017-09-19 | 2018-10-01 | |
| Complement Inhibition in aHUS Dialysis Patients CCX168 - Atypical Hemolytic Uremic Syndrome | Phase 2 | Terminated | Mario Negri Institute for Pharmacological Research | 6 | 2015-06-04 | 2017-11-14 |
| Effect of SVF Derived MSC in DCD Renal Transplantation SVFderived MSC transplantations, Basiliximab - Uremia | Phase 1 / Phase 2 | Unknown | Fuzhou General Hospital | 120 | 2014-12-01 | 2015-07-08 |
| Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies OMS721 - Thrombotic Microangiopathies | Phase 2 | Completed | Omeros Corporation | 58 | 2014-11-02 | 2024-08-28 |
| L-Cysteine in Peritoneal Dialysis L-cysteine, Placebo - Uremia | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2014-02-01 | 2015-06-30 |
| The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Eculizumab - Atypical Hemolytic Uremic Syndrome (aHUS) | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 2 | 2012-05-16 | 2017-03-10 |
| A Study in Participants With End-Stage Renal Disease LY2127399 - Kidney Failure, Chronic | Phase 2 | Completed | Eli Lilly and Company | 18 | 2011-04-01 | 2018-05-14 |
| Clonal Deletion on Living-Relative Donor Kidney Transplantation donor specific transfusion, MMF, Bortezomib, drugs added according to the immuno condition of the recipients - Renal Transplantation, Uremia | Phase 1 / Phase 2 | Unknown | Fuzhou General Hospital | 15 | 2011-03-01 | 2011-08-22 |
| Clinical and Biochemical Effects of Multipass Hemodialysis Multipass hemodialysis - Uremia | Phase 2 | Completed | Herlev Hospital | 12 | 2011-03-01 | 2013-07-09 |
| An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Eculizumab - Atypical Hemolytic-Uremic Syndrome | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 22 | 2010-09-01 | 2015-04-29 |
| An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Eculizumab - Atypical Hemolytic-Uremic Syndrome | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 44 | 2010-07-01 | 2017-05-30 |
| Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS eculizumab - Atypical Hemolytic Uremic Syndrome | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 5 | 2009-07-01 | 2015-07-23 |
| Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) eculizumab - Atypical Hemolytic Uremic Syndrome | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 15 | 2009-07-01 | 2015-07-23 |
| Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Eculizumab - Atypical Hemolytic Uremic Syndrome | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 16 | 2009-05-01 | 2015-07-23 |
Showing 20 of 24. Sign in to see all of them.
Atypical Hemolytic Uremic Syndrome (13) · Hemolytic-Uremic Syndrome (3) · Thrombotic Microangiopathies (3) · Carcinoma, Transitional Cell (1) · Disease Progression (1) · Hemolysis (1) · Inflammation (1) · Kidney Failure, Chronic (1) · Multiple Organ Failure (1) · Pruritus (1) · Purpura, Thrombotic Thrombocytopenic (1) · Renal Insufficiency (1) · Restless Legs Syndrome (1) · Thrombocytopenia (1)
Female Urogenital Diseases (24) · Female Urogenital Diseases and Pregnancy Complications (24) · Kidney Diseases (24) · Male Urogenital Diseases (24) · Urogenital Diseases (24) · Urologic Diseases (24) · Anemia (16) · Anemia, Hemolytic (16) · Blood Platelet Disorders (16) · Cytopenia (16) · Hematologic Diseases (16) · Hemic and Lymphatic Diseases (16) · Thrombocytopenia (15) · Hemolytic-Uremic Syndrome (13)
eculizumab (8) · Basiliximab (1) · Bortezomib (1) · Cysteine (1) · Dialysis (1) · Dipyridamole (1) · Exercise (1) · Lycopene (1) · Renal Dialysis (1) · Rituximab (1) · avacopan (1) · narsoplimab (1) · tabalumab (1)
Alexion Pharmaceuticals, Inc. (7) · Mario Negri Institute for Pharmacological Research (3) · Fuzhou General Hospital (2) · Inmunova S.A. (2) · Alnylam Pharmaceuticals (1) · Assaf-Harofeh Medical Center (1) · Children's Hospital Medical Center, Cincinnati (1) · Eli Lilly and Company (1) · Hamilton Health Sciences Corporation (1) · Herlev Hospital (1) · National Taiwan University Hospital (1) · NovelMed Therapeutics (1) · Omeros Corporation (1) · Yunfeng Xia (1)
Italy (8) · United States (7) · France (6) · Germany (6) · United Kingdom (6) · Canada (5) · Belgium (3) · China (3) · Netherlands (3) · Sweden (3) · Argentina (2) · Austria (2) · Lithuania (2) · Taiwan (2) · Australia (1)
David Barth, MD (1) · Fernando Goldbaum, PhD (1) · Gail Rock, MD (1) · Giuseppe Remuzzi, MD (1) · James G Heaf, MD DMSc (1) · Kathryn E Webert, E (1) · Nader Najafian, MD (1) · Ronan Foley, MD (1) · Sonata Jodele, MD (1) · Tan Jianming, MD, PhD (1) · Tan Jianming, MD,PhD (1) · William Clark, MD (1) · Yeong-Shiau Pu, MD, PhD (1)
PMID 33783815, PMID 23738544, PMID 21877169, PMID 23136214, PMID 25833956, PMID 25896788, PMID 26780484, PMID 34219224, PMID 34852172, PMID 35439028, PMID 37946262, PMID 40277027, PMID 41757982
2014 (2), 2018 (1)